ANIP ANI PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ANI PHARMACEUTICALS INC reported revenue of $266M (up 25.9% from a year earlier), net income of $24.7M and diluted EPS of $1.05; over the last four quarters revenue was $978M and net income $108M; for the fiscal year ended December 2025 revenue was $883M, up 43.8% on the year before.

ANIP annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $883M, gross profit n/a, operating income $111M, net income $78.0M (margin 8.8%), EPS $3.32
• Fiscal year ended Dec 2024: revenue $614M, gross profit n/a, operating income $584K, net income −$19.0M (margin -3.1%), EPS −$1.04
• Fiscal year ended Dec 2023: revenue $487M, gross profit n/a, operating income $47.0M, net income $19.0M (margin 3.9%), EPS $0.85
• Fiscal year ended Dec 2022: revenue $316M, gross profit n/a, operating income −$35.3M, net income −$48.0M (margin -15.2%), EPS −$3.05
• Fiscal year ended Dec 2021: revenue $216M, gross profit n/a, operating income −$39.8M, net income −$43.0M (margin -19.9%), EPS −$3.40

ANIP quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $266M (up 25.9% year over year), net income $24.7M, EPS $1.05
• Quarter ended Mar 31, 2026: revenue $237M (up 20.5% year over year), net income $29.5M, EPS $1.28
• Quarter ended Dec 31, 2025 (from the annual report): revenue $247M (up 29.6% year over year), net income $27.2M, EPS $1.14
• Quarter ended Sep 30, 2025: revenue $228M (up 53.6% year over year), net income $26.6M, EPS $1.13
• Quarter ended Jun 30, 2025: revenue $211M (up 53.1% year over year), net income $8.55M, EPS $0.36
• Quarter ended Mar 31, 2025: revenue $197M (up 43.4% year over year), net income $15.7M, EPS $0.69
• Quarter ended Dec 31, 2024 (from the annual report): revenue $191M (up 44.8% year over year), net income −$10.8M, EPS −$0.45
• Quarter ended Sep 30, 2024: revenue $148M (up 12.5% year over year), net income −$24.2M, EPS −$1.27
• Quarter ended Jun 30, 2024: revenue $138M (up 18.4% year over year), net income −$2.29M, EPS −$0.14
• Quarter ended Mar 31, 2024: revenue $137M (up 28.7% year over year), net income $18.2M, EPS $0.82
• Quarter ended Dec 31, 2023 (from the annual report): revenue $132M (up 39.7% year over year), net income $1.38M, EPS $0.05
• Quarter ended Sep 30, 2023: revenue $132M (up 57.3% year over year), net income $9.94M, EPS $0.45
• Quarter ended Jun 30, 2023: revenue $117M (up 57.8% year over year), net income $6.25M, EPS $0.29
• Quarter ended Mar 31, 2023: revenue $107M (up 65.6% year over year), net income $1.44M, EPS $0.06
• Quarter ended Dec 31, 2022 (from the annual report): revenue $94.2M (up 54.7% year over year), net income −$4.35M, EPS −$0.29
• Quarter ended Sep 30, 2022: revenue $83.8M (up 61.0% year over year), net income −$8.60M, EPS −$0.55
• Quarter ended Jun 30, 2022: revenue $73.9M (up 51.9% year over year), net income −$14.9M, EPS −$0.94
• Quarter ended Mar 31, 2022: revenue $64.5M (up 18.3% year over year), net income −$20.1M, EPS −$1.27
• Quarter ended Dec 31, 2021 (from the annual report): revenue $60.9M, net income −$24.5M, EPS −$1.87
• Quarter ended Sep 30, 2021: revenue $52.1M, net income −$4.45M, EPS −$0.37

ANIP cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $185M, share buybacks $12.2M
• Fiscal year ended Dec 2024: operating cash flow $64.0M, share buybacks $11.0M
• Fiscal year ended Dec 2023: operating cash flow $119M, share buybacks $4.99M
• Fiscal year ended Dec 2022: operating cash flow −$31.2M, share buybacks $1.96M
• Fiscal year ended Dec 2021: operating cash flow $3.32M, share buybacks $890K

ANIP balance sheet

• Jun 30, 2026: cash $360M, total assets $1.49B, total liabilities $897M, shareholders' equity $597M, long-term debt $280M
• Mar 31, 2026: cash $311M, total assets $1.42B, total liabilities $860M, shareholders' equity $562M, long-term debt $286M
• Dec 31, 2025: cash $286M, total assets $1.44B, total liabilities $900M, shareholders' equity $541M, long-term debt $292M
• Sep 30, 2025: cash $263M, total assets $1.41B, total liabilities $902M, shareholders' equity $506M, long-term debt $298M
• Jun 30, 2025: cash $218M, total assets $1.34B, total liabilities $881M, shareholders' equity $437M, long-term debt $301M
• Mar 31, 2025: cash $150M, total assets $1.29B, total liabilities $849M, shareholders' equity $419M, long-term debt $305M
• Dec 31, 2024: cash $145M, total assets $1.28B, total liabilities $856M, shareholders' equity $404M, long-term debt $309M
• Sep 30, 2024: cash $145M, total assets $1.29B, total liabilities $857M, shareholders' equity $406M, long-term debt $313M

What is ANIP's revenue?

ANI PHARMACEUTICALS INC reported $978M of revenue over its last four quarters, through June 30, 2026.

Is ANIP profitable?

Yes. ANI PHARMACEUTICALS INC earned $108M over the last four quarters.

What is ANIP's EPS?

Diluted earnings per share over the last four quarters were $4.60; $1.05 in the latest quarter.

ANIP ownership and insider trades · All stocks